TL;DR
- Idea: Decentralized science platform enabling community-driven biotech funding through AI-native research agents and milestone-based token incentives.
- Catalyst: V1 protocol upgrade scaling financial layer, $6.9M seed funding led by Maelstrom Fund, Upbit listing on October 20, 2025, and cross-chain bridge approval for BNB Chain on November 3, 2025.
- Risks: Niche DeSci narrative with uncertain adoption, regulatory scrutiny over biotech funding, volatile token performance since launch, and early-stage ecosystem with limited projects.
- Score: 7.00/ 10
Coin
- Name/ Ticker: Bio Protocol (BIO)
- Segment: DeSci
- Status: active
- Price: $0.060210
Key Metrics
- Market Cap: $105 688 698
- FDV: $198 269 405
- Circulating Supply: 1 769 745 956
- Total Supply: 3 320 000 000
Sources
Technology
- USP: AI-native decentralized science infrastructure with autonomous BioAgents for research funding and hypothesis generation.
- Core Technology: Blockchain-based launchpad for BioDAOs, vote-escrowed governance (veBIO), milestone-based bio/acc incentives, on-chain liquidity engine, and AI-driven research agents.
Roadmap
- 2025-09-17: Seed funding round led by Maelstrom Fund
- 2025-10-20: Listing on Upbit (KRW, BTC, USDT pairs)
- 2025-10-21: BioXP system update to restore expired XP
- 2025-10-24: Launch of Bio Launchpad Season 2 upgrades
- 2025-11-03: Snapshot approval for BNB Chain bridge and token contracts
- 2025-12-15: Planned deployment of BIO contracts on Base and Solana
Team & Investors
Team
- Co-founder & CEO — Paul Kohlhaas: Founder of Molecule, co-founder of VitaDAO, ex-ConsenSys, Swiss government blockchain
- Co-founder & CPO — Clemens Ortlepp: Founder of MTX Studio, product lead for decentralized tech
- Research & Community Lead — James Sinka: Blockchain developer and community operator
- Head of Operations — Erik Van Winkle: Experienced operations leader in DeSci and biotech funding
Investors
- Maelstrom Fund — Seed • 2025-09-17 • $6.90M
- Mechanism Capital — Seed • 2025-09-17
- Animoca Brands — Seed • 2025-09-17
- Presto Labs — Seed • 2025-09-17
- Atria Ventures — Seed • 2025-09-17
- Bridge34 — Seed • 2025-09-17
- Tophash Digital — Seed • 2025-09-17
Total funding: $6.90M
Tokenomics
- Utility: Governance (veBIO), staking (BioXP accrual), curation for BioDAO launches, liquidity provision, and access to AI BioAgents.
Pros & Cons
Strengths
- Strong seed backing by Maelstrom Fund and leading VC firms
- Unique AI-driven BioAgents automating research funding
- First-mover in the decentralized science (DeSci) sector
- Transparent milestone-based funding aligned with on-chain metrics
- Engaged community with 174M BIO staked and 161K DAO members
- Major CEX listings including Binance Launchpool and Upbit
- Cross-chain expansion imminent (BNB Chain, Base, Solana)
- High liquidity with $44M+ 24h trading volume
Weaknesses
- Narrow DeSci focus may limit broad market appeal
- Token price down over 90% from all-time high, signaling volatility
- Complex platform with high barrier to entry for non-technical users
- Regulatory uncertainty around biotech fundraising via crypto
- TVL of $12M is modest relative to FDV
- Core team size is small compared to growth ambitions
- Ecosystem early stage with few launched BioDAOs
- Competition from traditional biotech funding and grant models
Market Signals (7d)
- TVL trend: flat
- CEX volume trend: down
- Active addresses trend: down
Price Scenarios (target: 2026-05-27)
- Bear: $0.030000 — Assumes 50% decline from current price under a TVL contraction scenario with constant mcap/TVL ratio.
- Base: $0.060210 — Maintains current price, assuming stable TVL and adoption.
- Bull: $0.120000 — Projects 2× increase in TVL and market cap with sustained mcap/TVL ratio growth.
How to Buy & Store
CEX
- Binance
- Coinbase
- Kraken
- Upbit
- OKX
DEX
- Uniswap
- SushiSwap
- 1inch
- Balancer
- PancakeSwap
Storage
- MetaMask
- Ledger Nano S
- Trezor Model T
- Trust Wallet
- Coinbase Wallet
Verdict
Bio Protocol stands out as a pioneering DeSci infrastructure with solid funding and novel AI capabilities, but its niche focus and early stage pose adoption and execution risks.
Official Links
Source: Coin Research (internal)
Comments (0)